Enzyme-substrate complex competitive inhibition

Michaelis-Menten kinetics and, depending on their preference of binding to the free enzyme and/or the enzyme-substrate complex, competitive, uncompetitive, and noncompetitive inhibition patterns can be distinguished. For the purposes of this discussion it will be assumed that the initial equilibrium of free and bound substrate is established significantly faster than the rate of the chemical transformation of substrate to product, that is,... 

A competitive inhibitor resembles the substrate in its chemical structure and is able to combine with the enzyme to form an enzyme-inhibitor complex. In so doing it competes with the substrate for the active sites of the enzyme, and formation of the enzyme-substrate complex is inhibited. This type of inhibition may be reversed by the addition of excess substrate, which displaces the inhibitor, forming normal enzyme-substrate complexes. One of the best-known examples is provided by the sulphonamide drugs. The synthesis of folic acid from p-aminobenzoic acid (PABA) is a vital metabolic process in the bacteria controlled by these drugs. The similarity between PABA and sulphanUamide, released by the sulphonamides, is obvious ... 

The three most common types of inhibitors in enzymatic reactions are competitive, non-competitive, and uncompetitive. Competitive inliibition occurs when tlie substrate and inhibitor have similar molecules that compete for the identical site on the enzyme. Non-competitive inhibition results in enzymes containing at least two different types of sites. The inhibitor attaches to only one type of site and the substrate only to the other. Uncompetitive inhibition occurs when the inhibitor deactivates the enzyme substrate complex. The effect of an inhibitor is determined by measuring the enzyme velocity at various... 

Generally inhibitors are competitive or non-competitive with substrates. In competitive inhibition, the interaction of the enzyme with the substrate and competitive inhibitor instead of the substrate can be analysed with the sequence of reactions taking place as a result, a complex of the enzyme-inhibitor (El) is formed. The reaction sets at equilibrium and the final step shows the product is formed. The enzyme must get free, but the enzyme attached to the inhibitor does not have any chance to dissociate from the El complex. The El formed is not available for conversion of substrate free enzymes are responsible for that conversion. The presence of inhibitor can cause the reaction rate to be slower than the ordinary reaction, in the absence of the inhibitor. The sequence of reaction mechanisms is ... 

Uncompetitive inhibition is extremely rare in nature, and can arise when the inhibitor binds to the enzyme-substrate complex, rather than to the free enzyme, as in competitive inhibition [111]. In uncompetitive inhibition, an increase in the concentration of the inhibitor requires a disproportionately large increase in the concentration of the substrate to maintain the same metabolic turnover. 

Another type of inhibitor combines with the enzyme at a site which is often different from the substrate-binding site and as a result will inhibit the formation of the product by the breakdown of the normal enzyme-substrate complex. Such non-competitive inhibition is not reversed by the addition of excess substrate and generally the inhibitor shows no structural similarity to the substrate. Kinetic studies reveal a reduced value for the maximum activity of the enzyme but an unaltered value for the Michaelis constant (Figure 8.7). There are many examples of non-competitive inhibitors, many of which are regarded as poisons because of the crucial role of the inhibited enzyme. Cyanide ions, for instance, inhibit any enzyme in which either an iron or copper ion is part of the active site or prosthetic group, e.g. cytochrome c oxidase (EC 1.9.3.1). 

Non-competitive inhibitors. These inhibitors bind to the enzyme or the enzyme-substrate complex at a site other than the active site. This results in a decrease in the maximum rate of reaction, but the substrate can still bind to the enzyme. An analogous concept is that of allosteric inhibition. The site of binding of an allosteric inhibitor is distinct from the substrate binding site. In this case, the inhibitor is not a steric analog of the substrate and instead binds to the allosteric site (the phenomenon was termed thus by Monod and Jacob). 

It was previously thought that 5-FU inhibits the enzyme by classical competitive inhibition. However, it was found that 5-FU is a transition-state substrate, and it forms a covalent complex with tetrahydrofolate and the enzyme in the same way that the natural substrate does. The reaction, however, will not go to completion, since the fluoro-uridine derived from the antimetabolite remains attached to the enzyme, and the latter becomes irreversibly deactivated. Recovery can occur only through the synthesis of new enzyme. Fluorouracil is used in the treatment of breast cancer and has found limited use in some intestinal carcinomas. Unfortunately, this drug has the side effects usually associated with antimetabolites. Its prodrug, fluorocytosine (8.35, which is also an antifungal agent) is better tolerated. 

Other Reversible Inhibition Mechanisms In noncompetitive inhibition, an inhibitor is considered to combine with both an enzyme and the enzyme-substrate complex. Thus, the following reaction is added to the competitive inhibition mechanism ... 

Since preliminary studies showed that 6-hydroxymellein-O-methyl-transferase activity was appreciably inhibited in the presence of the reaction products, the mode of product inhibition of the enzyme was studied in detail in order to understand the regulatory mechanism of in vivo methyltransfer. It is well known that S-adenosyl-Z.-homocysteine (SAH), which is a common product of many O-methyltransferases that use SAM as methyl donor, is usually a potent inhibitor of such enzymes. In the 6-hydroxymellein-Omethyltransferase catalyzing reaction another product of this enzyme, 6-methoxymellein, has pronounced inhibitory activity, in addition to SAH. Since the specific product of the transferase reaction, 6-methoxymellein, is capable of inhibiting transferase activity [88], this observation suggests that activity of the transferase is specifically regulated in response to increases in cellular concentrations of its reaction products in carrot cells. It has been also found that 6-methoxymellein inhibits transferase activity with respect not only to 6-hydroxymellein but also to SAM, competitively. This competitive inhibition was also found in SAH as a function of the co-substrates of the enzyme [89]. It follows that the reaction catalyzed by 6-hydroxymellein-O-methyltransferase proceeds by a sequential bireactant mechanism in which the entry of the co-substrates to form the enzyme-substrate complexes and the release of the co-products to generate free enzyme take place in random order [Fig. (7)]. This result also implies that 6-methoxymellein and SAH have to associate with the free transferase protein to exhibit their inhibitory activities, and cannot work as the inhibitors after the enzyme forms complexes with the the substrate. If, therefore, 6-hydroxymellein-O-methyltransferase activity is controlled in vivo by its specific product 6-methoxymellein, this compound should... 

Reversible inhibition occurs rapidly in a system which is near its equilibrium point and its extent is dependent on the concentration of enzyme, inhibitor and substrate. It remains constant over the period when the initial reaction velocity studies are performed. In contrast, irreversible inhibition may increase with time. In simple single-substrate enzyme-catalysed reactions there are three main types of inhibition patterns involving reactions following the Michaelis-Menten equation competitive, uncompetitive and non-competitive inhibition. Competitive inhibition occurs when the inhibitor directly competes with the substrate in forming the enzyme complex. Uncompetitive inhibition involves the interaction of the inhibitor with only the enzyme-substrate complex, while non-competitive inhibition occurs when the inhibitor binds to either the enzyme or the enzyme-substrate complex without affecting the binding of the substrate. The kinetic modifications of the Michaelis-Menten equation associated with the various types of inhibition are shown below. The derivation of these equations is shown in Appendix S.S. 

Types of enzyme inhibition, (a) A competitive inhibitor competes with the substrate for binding at the same site on the enzyme, (b) A noncompetitive inhibitor binds to a different site but blocks the conversion of the substrate to products, (c) An uncompetitive inhibitor binds only to the enzyme—substrate complex. (E = enzyme S = substrate.)... 

Corey also pointed out that 16 reflects the transition-state of an enzyme-substrate complex. Its formation was later supported by the observation of Michaelis-Menten-type kinetics in dihydroxylation reactions and in competitive inhibition studies [37], This kinetic behavior was held responsible for the non-linearity in the Eyring diagrams, which would otherwise be inconsistent with a concerted mechanism. Contrary, Sharpless stated that the observed Michaelis-Menten behavior in the catalytic AD would result from a step other than osmylation. Kinetic studies on the stoichiometric AD of styrene under conditions that replicate the organic phase of the catalytic AD had revealed that the rate expression was clearly first-order in substrate over a wide range of concentrations [38],... 

Competitive and non-competitive inhibitions are easily distinguishable from the Lineweaver-Burk plot. In the case of competitive inhibitors, the intercept on the 1/CS axis increases while the intercept of the 1/v axis remains unchanged by the addition of the inhibitor. Conversely, with a non-competitive inhibitor, only the 1/v axis intercept increases. The effect of competitive inhibitors can be reversed by increasing the substrate concentration. Where the enzyme or the enzyme substrate complex is made inactive, a non-competitive inhibitor decreases Vmax of the enzyme, but Km remains constant. 

Competitive inhibition occurs, when substrate and inhibitor compete for binding at the same active site at the enzyme. Based on the Michaelis-Menten kinetics, Vmax is unchanged whereas Km increases. In case of noncompetive inhibition, the inhibitor and the substrate bind to different sites at the enzyme. Vmax decrease whereas the Km value is unaffected. Binding of the inhibitor only to the enzyme-substrate complex is described as uncompetitive inhibition. Both, Vmax and Km decrease. Finally, mixed (competitive-noncompetitive) inhibition occurs, either the inhibitor binds to the active or to another site on the enzyme, or the inhibitor binds to the active site but does not block the binding of the substrate. 

To be used effectively, the mechanisms through which inhibitors exert their effects need to be understood. For example, competitive inhibitors compete with physiological substrates for binding sites. Their effect depends on the relative concentrations of substrates and the inhibitor and the degree of inhibition depends on the number of active sites occupied by the inhibitor versus the metabolic substrate. In contrast, noncompetitive inhibitors bind to parts of the enzyme other than the substrate binding site, so the degree of inhibition depends only on the inhibitor and not the substrate concentration. This type of inhibition is typically irreversible and reduces the amount of total enzyme available to catalyze a particular reaction. Uncompetitive inhibition occurs when the inhibitor binds to the enzyme-substrate complex and prevents the reaction from being catalyzed. 

Noncompetitive inhibitors interact reversibly with enzymes to form an inactive species, effectively removing active enzyme and thus interfering with the rate of conversion of substrate to product. The inhibitor may interact with free enzyme, or with the enzyme-substrate complex. The key feature of noncompetitive inhibition that distinguishes it from competitive inhibition is that inhibition does not affect the apparent affinity of the enzyme for its substrate (i.e., the apparent Km). For example, a noncompetitive inhibitor may bind in a region remote from the active site to cause a reversible change in enzyme tertiary structure that completely prevents substrate binding and product formation. In this type of inhibition, the quantity of active enzyme appears to decrease as inhibitor concentration increases, so that the apparent Fmax for the reaction decreases. 

In noncompetitive inhibition, the inhibitor does not usually bear any structural resemblance to the substrate, and it binds to the enzyme at a site distinct from the substrate binding site. No competition exists between the inhibitor and the substrate, and the inhibition cannot be overcome by increase of substrate concentration. An inhibitor may bind either to a free enzyme or to an enzyme-substrate complex in both cases, the complex is catalytically inactive ... 

Specific small molecules or ions can inhibit even nonallosteric enzymes. In irreversible inhibition, the inhibitor is covalently linked to the enzyme or bound so tightly that its dissociation from the enzyme is very slow. Covalent inhibitors provide a means of mapping the enzyme s active site. In contrast, reversible inhibition is characterized by a more rapid equilibrium between enzyme and inhibitor. A competitive inhibitor prevents the substrate from binding to the active site. It reduces the reaction velocity by diminishing the proportion of enzyme molecules that are bound to substrate. Competitive inhibition can be overcome by raising the substrate concentration. In uncompetitive inhibition, the inhibitor combines only with the enzyme-=substrate complex. In noncompetitive inhibition, the inhibitor decreases the turnover number. Uncompetitive and noncompetitive inhibition cannot be overcome by raising the substrate concentration. 

In textbooks dealing with enzyme kinetics, it is customary to distinguish four types of reversible inhibitions (i) competitive (ii) noncompetitive (iii) uncompetitive and, (iv) mixed inhibition. Competitive inhibition, e.g., given by the product which retains an affinity for the active site, is very common. Non-competitive inhibition, however, is very rarely encountered, if at all. Uncompetitive inhibition, i.e. where the inhibitor binds to the enzyme-substrate complex but not to the free enzyme, occurs also quite often, as does the mixed inhibition, which is a combination of competitive and uncompetitive inhibitions. The simple Michaelis-Menten equation can still be used, but with a modified Ema, or i.e. ... 

Competitive inhibitors are so named because they compete for the active site with the native substrate, meaning that only enzyme-inhibitor or enzyme-substrate complex formation is possible (Fig. 7-3a). In this case, the inhibition constant, or enzyme-inhibitor complex dissociation constant, can be defined ... 

Inhibitors structurally related to the substrate may be bound to the enzyme active center and compete with the substrate (competitive inhibition). If the inhibitor is not only bound to the enzyme but also to the enzyme-substrate complex, the active center is usually deformed and its function is thus impaired in this case the substrate and the inhibitor do not compete with each other (noncompetitive inhibition). Competitive and noncompetitive inhibition effect the enzyme kinetics differently. A competitive inhibitor does not change but increases. Km (Fig. 25a) in contrast, noncompetitive inhibition results in an unchanged Km and an increased vmax (Fig. 25b). Some enzymes, e.g. invertase, are inhibited by high product concentration (product inhibition). 

Reactivating oximes have been designed to fit optimally into the active site of the enzyme acetylcholinesterase to maximize dephosphyla-tion. This property inevitably implies competition with the substrate of AChE. The K values describing the dissociation constant of the oxime from the substrate-free enzyme is around 300 pM, while the Kn value describing the dissociation constant of the oxime from the enzyme-substrate complex is about one order of magnitude higher (Mast, 1997 Eyer, 2003). That means 10 pM oxime is virtually without effect while 100 pM is expected to inhibit AChE to an appreciable extent. Such a peak concentration may... 

Most inhibition of enzymes is competitive, uncompetitive, or noncompetitive. Competitive inhibitors reversibly compete with substrate for the same site on free enzyme. Uncompetitive inhibitors bind only to the enzyme-substrate complex and not the free enzyme. Noncompetitive inhibitors can bind to both the enzyme and the enzyme-substrate complex. 

We may now consider the case of uncompetitive inhibition (Scheme 3). This may be thought of almost as the opposite of competitive inhibition, since the assumption is that the inhibitor, I, can bind only to the enzyme-substrate complex EA, to form... 

The simplest mechanism which explains competitive inhibition is one in which there is a single intermediate—the enzyme-substrate complex ES "=and in which only the enzyme can combine with the inhibitor to form the complex El. The mechanism can be written as... 

The second case are reversible or noncolvalent inhibitors. If an inhibitor binds reversibly at the same site as the substrate, the inhibition is referred to as competitive. In other words for competitive inhibition - inhibitor (I) binds only to E, not to the enzyme substrate complex ES. For noncompetitive inhibition - inhibitor (I) binds either to E and/or to ES. A further type of reversible inhibition, uncompetitive, occurs when the inhibitor binds only to the complex enzyme-substrate ES and not to the free enzyme. This is a very rare case and sometimes is even referred to as a hypothetical case. 

---